Beverly Moy

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Biomarker-driven prescribing patterns in <i>ESR1</i> <i> ^mut </i> ER+/HER2- metastatic breast cancer (mBC).

  Journal of Clinical Oncology · 2026-05-28

• Evaluating tumor genomics and FES-PET in estrogen receptor–positive (ER+) breast cancer (BC).

  Journal of Clinical Oncology · 2026-05-28

• Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial

  The Lancet Oncology · 2026-04-27

• Mailed Outreach for Colorectal Cancer Screening in Community Health Centers

  JAMA Internal Medicine · 2026-04-27 · 1 citations

• Guidance for Community Engagement With Underserved Populations in Cancer Care

  JCO Oncology Practice · 2026-01-28

• Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study

  Breast Cancer Research and Treatment · 2025-11-21

• Development and refinement of a nurse-led, culturally sensitive intervention for adjuvant endocrine therapy initiation among patients with breast cancer

  European Journal of Oncology Nursing · 2025-10-15 · 1 citations

• Selection biases in the systematic collection of breast biobank specimens

  npj Breast Cancer · 2025-08-01 · 1 citations

• Abstract P4-10-12: Abemaciclib monotherapy after disease progression on prior CDK4/6 inhibitors in patients with metastatic hormone-receptor positive breast cancer

  Clinical Cancer Research · 2025-06-13

• Abstract P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis

  Clinical Cancer Research · 2025-06-13

• Abstract P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy &amp; a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial

  Clinical Cancer Research · 2025-06-13

• A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.

  Journal of Clinical Oncology · 2025-05-28 · 11 citations

• Supplementary Figure S1 from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Supplemental Table S1 from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• Data from TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerPreprint

  2025-05-15

• 276: IMPLEMENTING LINGUISTICALLY TAILORED COLORECTAL CANCER RISK ASSESSMENT IN A MULTI-SITE PRAGMATIC CLINIC TRIAL TO IMPROVE SCREENING IN COMMUNITY HEALTH CENTERS

  Gastroenterology · 2025-05-01

• 1128: COMPARING THE EFFECTIVENESS OF TWO MAILED OUTREACH INTERVENTIONS TO INCREASE COLORECTAL CANCER SCREENING IN COMMUNITY HEALTH CENTERS

  Gastroenterology · 2025-05-01

• Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization

  UNC Libraries · 2025-04-22

• Abstract 3360: Pre- and post-operative analysis of circulating tumor DNA in patients with breast cancer treated with neoadjuvant therapy using a tissue-free, methylation-based approach

  Cancer Research · 2025-04-21

• Abstract 2024: Circulating tumor DNA detectability and targetability in patients undergoing neoadjuvant therapy for localized breast cancer

  Cancer Research · 2025-04-21